



ASX ANNOUNCEMENT

29 April 2025

Vitrafy Life Sciences Quarterly Activities Report & Appendix 4C – Quarter 3, Financial Year 2025

Melbourne, Australia: Vitrafy Life Sciences Limited (ASX: VFY) (“**Vitrafy**” or “**the Company**”), an Australian innovator in cryopreservation solutions, is pleased to present its Quarterly Activities Report and Appendix 4C Cash Flow report for the third quarter ended 31 March 2025 (“**Q3**”) of Financial Year 2025 (“**FY2025**”).

Highlights


- Successful completion of phase 1 blood platelet study with the US Army Institute of Surgical Research (“**USAISR**”).
- Awarded a \$4.8 million Industry Growth Program Grant from the Australian Government to support the development of VCU2 and facilitate commercialisation plans.
- Continued progress in the prioritised Animal Health application areas of aquaculture and bovine semen cryopreservation.
- Continued development of Vitrafy’s Cryopreservation Unit 2.0 (VCU2) and upgrade of the LifeChain™ software ahead of go-to-market launch in the second half of 2025.
- Good progress in business development activities focused on the U.S. market, with discussions progressing in all target sectors.
- Successful commencement of U.S operations with first key executive hired to lead the buildout of internal capabilities.
- Strong financial position, with closing cash and term deposits of ~\$34m to fund the Company’s continued development and commercialisation activities

Commercialisation Update

Animal Health - Aquaculture

During the quarter, Vitrafy continued to develop the domestic aquaculture market through paid commercial work with Huon aquaculture. In February, Vitrafy assisted with the summer fertilisation program where both fresh and cryopreserved salmon milt were used to fertilise fresh eggs.

As part of the fertilisation program, the summer insemination program included fertilisation from fresh salmon milt, Vitrafy cryopreserved salmon milt and cryopreserved milt from a competitor. Pleasingly, the post-thaw fertilisation results indicated the average fertilisation percentages using Vitrafy cryopreserved salmon milt were comparable to fresh salmon milt:



In addition to the summer fertilisation program, Vitrafy and Huon planned the upcoming May cryopreservation cycle. In May, Vitrafy will work with Huon to cryopreserve a minimum of 750 packs of neo-male broodstock salmon milt, up from 500 packs last May.

This work has led to discussions with other aquaculture providers in the Australian market, with Vitrafy in discussions to undertake a paid pilot with another domestic salmon provider in the coming quarter.

Since 2022, the quantity of salmon milt packs cryopreserved by Vitrafy has had a compound annual growth rate (CAGR) of 55.3% per annum. This consistent growth combined with the inbound aquaculture interest in the domestic market is reflective of the growing interest in artificial insemination within the industry and how it can positively impact hatchery and harvest management.

Vitrafy continues to invest resources in growing its aquaculture business, with a specific focus on developing the domestic market in the short term. Vitrafy will assess opportunities within this industry more broadly given the established value proposition and early market adoption by industry leaders.

Bovine

During the quarter, Vitrafy finalised the scope of works and planning for the on-site trial to be completed with collaboration partner, Select Sires Inc (“SSI”). Following the successful first phase trials where Vitrafy cryopreserved bovine semen and compared favourably to industry benchmark standards, Vitrafy will be completing an on-site trial at SSI’s Ohio facility. Testing will be completed during the current quarter with results and the next steps under the collaboration agreement are expected to be released in quarter 4. The results generated from the on-site trial will act as a gating item for further engagement with SSI whilst importantly retaining all rights and intellectual property for Vitrafy in the bovine industry.



Human Health

Blood and Blood Products

As announced to market in early April, during the period, USAISR successfully completed phase 1 of the blood platelets project with using the Vitrafy technology. Validation testing completed under phase 1 of the collaboration project included Vitrafy's Cryopreservation Technology, and its proprietary processes and protocols for blood platelets with, and without, cryoprotectants being independently tested by the USAISR.

With validation testing being focused on commercial unit sizes, samples were collected from 8 healthy donors and 24 units were tested in total, measuring post thaw recovery and functionality metrics. Importantly, all cryopreserved protocols evaluated using the Vitrafy Cryopreservation Technology, including those with and without cryoprotective agents, resulted in post-thaw recoveries greater than 88%. All Vitrafy proprietary protocols and processes had post-thaw functionality measurements exceeding all regulatory and industry standards required to be used for human health applications.

With successful completion of phase 1 of the blood platelets project, a gating item for the collaboration-to-commercialisation pathway, Vitrafy and the USAISR will now proceed to the next phase which includes validation of higher unit throughputs and replicates, and more detailed protocol selection. This phase is expected to be completed during 2025, as the parties progress to commercial discussions and planning.

Reflective of the strong relationship, the USAISR and Vitrafy are also discussing cross-collaboration on joint marketing and education opportunities surrounding the innovative nature of Vitrafy's Cryopreservation Technology. It is expected this will include media coverage via military channels, conference presentations and joint efforts to educate the market surrounding the value of Vitrafy's Cryopreservation Technology in delivering a higher standard of trauma care in military and civilian environments.

Outside of the collaboration with the USAISR, Vitrafy has generated a number of business development opportunities within the blood and blood products sector in North America. These opportunities span the cryopreservation supply chain for blood and blood products with increased awareness of the strong results achieved with collaboration partners providing a high-degree of interest in Vitrafy's Cryopreservation Technology.

Cell & Gene Therapy

Vitrafy continues to progress conversations for use of its Cryopreservation Technology in CGT settings. With active conversations across Australia and North America with participants within the CGT industry, Vitrafy is continuing to invest in validation work, with and without collaboration partners, to build out a robust data base and validate the value proposition for potential users. Vitrafy is currently working closely with industry leaders and partners to bring its technology to market in the area of CGT.



Operational Update

U.S. Market Expansion

As outlined in the half-year update, Vitrafy has commenced establishing a formal presence in the United States. With the increased focus on U.S. market penetration, the appointment of a US-based Vice President of Business Development was finalised during the quarter. Vitrafy is pleased to welcome Brad Neal-Taylor to this position. Brad, who holds a PhD in genetics and molecular biology, has extensive experience in the cellular therapy sector and within the broader scientific community, holding various leadership roles in technical support and training, product management, and marketing.

With the focus on commercialisation, the next step will be to scale the team in the U.S. whilst simultaneously leveraging existing partnership networks to support scaling up operations efficiently.

Product Development

During the period, Vitrafy made good progress on its technology development, which is critical to the Company's commercialisation journey. The development of the Cryopreservation Unit 2.0 (VCU2) in partnership with health-tech company, Planet Innovation, is progressing on schedule for its first commercial version in the second half of calendar year 2025.


The LifeChain™ software upgrade also remains on track. Key appointments to the development team have enhanced internal capability and the focus of the past quarter has been on navigating regulatory considerations and algorithm development, with both streams yielding positive results. Work will continue into Q4, with product launch expected in the first half of FY2026.

Vitrafy was awarded a \$4.8 million Industry Growth Program (IGP) Grant by the Australian Government to support the Company's VCU2 project. This funding will accelerate the global commercialisation of Vitrafy's Cryopreservation Technology, particularly through the development of the VCU2 device and driving the translation of research in blood and blood products into commercial outcomes.

The grant reflects the Government's recognition of Vitrafy's solutions in enhancing cell survival and functionality compared to existing industry standards and provides a significant boost to commercialisation plans.

Financial Results

Vitrafy ended Q3 with cash at the bank of A\$13.9m and short-term financial assets (term deposits) of A\$20.1m. Leaving total liquidity at ~\$34.0m. During the quarter, average monthly expenditure remained steady at ~A\$1.1m cash outflow per month with inflows from receipts from customers, interest and grant income resulting in a net cash movement for the quarter of approximately A\$(0.5)m:



With the expanded headcount and increased work undertaken as part of the product development activities within Q3, average monthly burn will increase in Quarter 4. Vitrafy will continue to be disciplined in its fiscal management, focusing capital allocation on activities that progress our commercialisation.

As per ASX Listing Rule 4.7C.2., the expenditure related to the Use of Funds lodged with the ASX on 6 November 2024 for the quarter ending 31 March 2025 was \$3.05m. A summary of expenditure to date is attached as part of this announcement.

As noted in item 6 of the Company's Appendix 4C, payments made to directors, related parties and their associates totalled \$341,000 for the quarter. All payments comprised Non-Executive Directors' fees and Executive Director remuneration.

Outlook

Looking forward, Vitrafy's focus remains on commercialisation. With the continued build out of the Company's capabilities in key markets, Vitrafy will continue to build out the business development pipeline ahead of the launch of our next generation devices later this calendar year.

CEO of Vitrafy, **Kate Munnings**, commented on the quarter's performance "It was pleasing to see the progress made during the quarter. Whilst the successes achieved in the quarter were excellent, our team remains focused on delivery and execution on the core areas of our strategy that was outlined to investors at the time of the IPO."



Investor Briefing

Vitrafy will be hosting a quarterly investor briefing on Friday, 2 May 2025 at 9am (AEST). If you would like to join the call, please register via the following link to receive briefing invite:

https://zoom.us/webinar/register/WN_ne0woJWrSwC89S75cgK_jg

ENDS

This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Investor and Media Relations

Simon Martin

Chief Financial Officer

investors@vitrafy.com

About Vitrafy

Vitrafy has developed a proprietary range of smart cryopreservation hardware and Lifechain™, a cloud-based software platform, to offer a complete cryopreservation solution. This integrated system ensures the preservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the storage process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets. Vitrafy is headquartered in Melbourne, Australia, has an ISO13485 accredited Manufacturing Facility and Laboratory in Ballarat, Victoria and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit [vitrafy.com](https://www.vitrafy.com).

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Vitrafy Life Sciences Ltd

ABN

48 622 720 254

Quarter ended ("current quarter")

31 March 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	12	52
1.2 Payments for		
(a) research and development	(1,063)	(2,647)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(1,541)	(4,023)
(f) administration and corporate costs	(559)	(2,615)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	161	211
1.5 Interest and other costs of finance paid	(6)	(18)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	2,640	4,663
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(356)	(4,377)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	(2)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (term deposits with maturities greater than 3 months and restricted deposit for credit card facility)	(75)	*(20,075)
2.6	Net cash from / (used in) investing activities	(75)	(20,077)

* In addition to the cash and cash equivalents balance above as at 31 March 2025, the Company holds an additional \$20 million in term deposits with maturity terms ranged between 6 months and 9 months (31 December 2024: \$20 million) and a restricted deposit of \$75,000 for credit card facility (31 December 2024: nil), classified in the statement of financial position as short-term investments in accordance with AASB.

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	35,000
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	317
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(32)	(3,248)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (lease liabilities)	(21)	(61)
3.10	Net cash from / (used in) financing activities	(53)	32,008

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	14,451	6,413
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(356)	(4,377)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(75)	(20,077)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(53)	32,008
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	*13,967	*13,967

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	13,967	14,451
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	*13,967	*14,451

* In addition to the cash and cash equivalents balance above as at 31 March 2025, the Company holds an additional \$20 million in term deposits with maturity terms ranged between 6 months and 9 months (31 December 2024: \$20 million) and a restricted deposit of \$75,000 for credit card facility (31 December 2024: nil), classified in the statement of financial position as short-term investments in accordance with AASB.

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	341
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	75	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		75
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. The company has put in place a credit card facility with CBA during the current quarter which is secured by a cash deposit of \$75,000. As at 31 March 2025 the facility was unused.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(356)
8.2	Cash and cash equivalents at quarter end (item 4.6)	13,967
8.3	Unused finance facilities available at quarter end (item 7.5)	75
8.4	Total available funding (item 8.2 + item 8.3)	*14,042
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	39.4
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i> <i>* In addition to the cash and cash equivalents balance noted above at 8.4, the Company holds an additional \$20.08 million in term deposits, classified in the statement of financial position as short-term investments in accordance with AASB, due to the maturity date being greater than 3 months. As a result, the estimated quarters of funding available will be greater than the figure provided in 8.5 due to holding these additional short-term investments. On a pro-forma basis with the \$20.08 million included, the Company would have estimated quarters of funding available amounting to 95.8.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer: N/A 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? Answer: N/A 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? Answer: N/A <i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

29 April 2025

Date:

The Board of Directors

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

Use of Funds Statement

As per ASX Listing Rule 4.7C.2., the expenditure related to the Use of Funds lodged with the ASX on 6 November 2024 for the quarter ending 31 March 2025 was ~\$3.05m. A summary of expenditure to date is outlined below:

	Per prospectus \$'000	Cumulative as at 31 December 2024 \$'000	For the quarter ended 31 March 2025 \$'000	Cumulative as at 31 March 2025 \$'000	Balance remaining \$'000
Market development					
- Business development, marketing and North American expansion	4,100	33	52	85	4,015
- Regulatory approvals	2,000	76	93	169	1,831
- Operational team build-out to service trials and commercial arrangements	4,800	250	731	981	3,819
	10,900	359	876	1,235	9,665
Technology Development					
- Hardware v2.0 design and development	7,600	637	617	1,254	6,346
- Software development	5,200	137	516	653	4,547
- Ongoing research & development activities	1,500	11	130	141	1,359
	14,300	785	1,263	2,048	12,252
Capital Expenditure					
- Intellectual property protection	500	16	120	136	364
- Operational equipment	700	2	-	2	698
	1,200	18	120	138	1,062
Working capital	11,600	772	758	1,530	10,070
Costs of the Offer	3,400	3,216	32	3,248	152
	41,400	5,150	3,050	8,200	33,201